Treace Medical Concepts, Inc. (TMCI)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$4.27-0.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Treace Medical Concepts, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	67.4M
EPS	—	-0.068
FY 2026 · Annual
Revenue	$204M–$212M	207.56M
This compares to previous revenue	$202M–$212M	—
EPS	—	-0.85
FY 2027 · Annual
Revenue	—	221.64M
EPS	—	-0.774

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce cash usage by 50% in 2026 versus 2025	The company aims to cut cash usage by 50% in 2026.	Improving	cash usage reduction less than 25% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Year-to-date cash usage was reduced by 57% or $3.6 million through 2026-Q2 compared to the same period in 2025. Management has consistently reiterated the goal of approximately 50% cash usage reduction for full-year 2026, and the trajectory is delivering against this target. Delivery assessment Oct 24, 2026
EPS improves but remains negative near -$0.9 in 2026	A supporting condition in Treace Medical Concepts, Inc.'s published investment case. The stated target is EPS around -$0.9.	Intact	EPS worse than -$1.0 in FY26	Diluted EPS: $-0.24 per share FY2026-Q2; GAAP. Published target: EPS around -$0.9. Target period is not explicitly aligned with this observation. Source published Aug 7, 2026-0.24 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 94650a59-9cd0-4229-9c61-9b247d7d41df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Year-to-date cash usage was reduced by 57% or $3.6 million through 2026-Q2 compared to the same period in 2025. Management has consistently reiterated the goal of approximately 50% cash usage reduction for full-year 2026, and the trajectory is delivering against this target. Delivery assessment Oct 24, 2026
Revenue grows to about $207 million in 2026	Treace Medical is growing sales about 5% a year to over $200 million in 2026.	Intact	revenue falls below $202 million in FY26	Revenue: $45.376M FY2026-Q2; GAAP. Published target: ~$207 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 202645,376,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 94650a59-9cd0-4229-9c61-9b247d7d41df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.22B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$221,804,740	1 / 5
2026-07-25	Unavailable	$221,804,740	1 / 5
2026-07-26	Unavailable	$221,804,740	1 / 5
2026-07-27	Unavailable	$221,804,740	1 / 5
2026-07-28	Unavailable	$221,804,740	1 / 5
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	$221,804,740	1 / 5
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	$221,804,740	1 / 5
2026-08-03	Unavailable	$221,804,740	1 / 5
2026-08-04	Unavailable	$221,804,740	1 / 5
2026-08-05	Unavailable	$221,804,740	1 / 5
2026-08-06	Unavailable	$221,804,740	1 / 5
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	$221,804,740	1 / 5
2026-08-10	Unavailable	$221,804,740	1 / 5
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	2 / 4
2026-08-31	Unavailable	Unavailable	2 / 4
2026-09-01	Unavailable	Unavailable	2 / 4
2026-09-02	Unavailable	Unavailable	2 / 4
2026-09-03	Unavailable	Unavailable	2 / 4
2026-09-04	Unavailable	Unavailable	2 / 4
2026-09-05	Unavailable	Unavailable	2 / 4
2026-09-06	Unavailable	Unavailable	2 / 4
2026-09-07	Unavailable	Unavailable	2 / 4
2026-09-08	Unavailable	Unavailable	2 / 4
2026-09-09	Unavailable	Unavailable	2 / 4
2026-09-10	Unavailable	Unavailable	2 / 4
2026-09-11	Unavailable	Unavailable	2 / 4
2026-09-12	Unavailable	Unavailable	2 / 4
2026-09-13	Unavailable	Unavailable	2 / 4
2026-09-14	Unavailable	Unavailable	2 / 4
2026-09-15	Unavailable	Unavailable	2 / 4
2026-09-16	Unavailable	Unavailable	2 / 4
2026-09-17	Unavailable	Unavailable	2 / 4
2026-09-18	Unavailable	Unavailable	2 / 4
2026-09-19	Unavailable	Unavailable	2 / 4
2026-09-20	Unavailable	Unavailable	2 / 4
2026-09-21	Unavailable	Unavailable	2 / 4
2026-09-22	Unavailable	Unavailable	2 / 4
2026-09-23	Unavailable	Unavailable	2 / 4
2026-09-24	Unavailable	Unavailable	2 / 4
2026-09-25	Unavailable	Unavailable	2 / 4
2026-09-26	Unavailable	Unavailable	2 / 4
2026-09-27	Unavailable	Unavailable	2 / 4
2026-09-28	Unavailable	Unavailable	2 / 4
2026-09-29	Unavailable	Unavailable	2 / 4
2026-09-30	Unavailable	Unavailable	2 / 4
2026-10-01	Unavailable	Unavailable	2 / 4
2026-10-02	Unavailable	Unavailable	2 / 4
2026-10-03	Unavailable	Unavailable	2 / 4
2026-10-04	Unavailable	Unavailable	2 / 4
2026-10-05	Unavailable	Unavailable	2 / 4
2026-10-06	Unavailable	Unavailable	2 / 4
2026-10-07	Unavailable	Unavailable	2 / 4
2026-10-08	Unavailable	Unavailable	2 / 4
2026-10-09	Unavailable	Unavailable	2 / 4
2026-10-10	Unavailable	Unavailable	2 / 4
2026-10-11	Unavailable	Unavailable	2 / 4
2026-10-12	Unavailable	Unavailable	2 / 4
2026-10-13	Unavailable	Unavailable	2 / 4
2026-10-14	Unavailable	Unavailable	2 / 4
2026-10-15	Unavailable	Unavailable	2 / 4
2026-10-16	Unavailable	Unavailable	2 / 4
2026-10-17	Unavailable	Unavailable	2 / 4
2026-10-18	Unavailable	Unavailable	2 / 4
2026-10-19	Unavailable	Unavailable	2 / 4
2026-10-20	Unavailable	Unavailable	2 / 4
2026-10-21	Unavailable	Unavailable	2 / 4
2026-10-22	Unavailable	Unavailable	2 / 4
2026-10-23	Unavailable	Unavailable	2 / 4
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	3	1
2026-06-01	1	3	1
2026-07-01	1	3	1
2026-08-01	1	3	1
2026-09-01	1	3	1
2026-10-01	1	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce cash usage by 50% in 2026 versus 2025Direct metric needs a verified mapping
EPS improves but remains negative near -$0.9 in 2026Diluted EPS: $-0.24 per share
Revenue grows to about $207 million in 2026Revenue: $45.376M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-82.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Treace Medical Concepts, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth and execution story, not a proven durable compounder. The multi-year view is on watch: management is stable, but recent financial performance is weak and the business remains loss-making.

What's priced into Treace Medical Concepts, Inc.

The valuation evidence is mixed and low confidence: TMCI is described as cheap versus peers, while also showing a 47% premium versus peers. The expectations gap is negative, and the market-pricing tag is justified, but the evidence does not show exactly which operating expectations are reflected.

What the fundamentals likely do

Near term, cash usage is moving in the right direction: it was down 57% year to date through the second quarter, against a full-year goal of about 50%. Revenue fell in the first half, and full-year guidance allows for a decline of up to 4%; surgeon adoption of the expanded bunion portfolio rose from 35% to about 40% between the first and second quarters. The recent earnings beats are positive, but the longer-term trajectory still depends on execution and the company’s ability to improve weak results.

What Treace Medical Concepts, Inc. hinges on

A favorable shift would require guidance to recover after it was lowered as of August 7, alongside continued progress in cash use and surgeon adoption. The case also depends on revenue stabilizing rather than weakening further. A softer jobs backdrop could weigh on cyclical businesses, while stronger results and guidance from sector peers could support the healthcare backdrop.